Leifheit Aktiengesellschaft

  • WKN: 646450
  • ISIN: DE0006464506
  • Land: Deutschland

Nachricht vom 13.10.2021 | 13:14

Leifheit Aktiengesellschaft: Distortions of the global supply chain affects EBIT in the third quarter, earnings (EBIT) forecast adjusted to EUR 15 to 20 million

Leifheit Aktiengesellschaft / Key word(s): Quarter Results/Change in Forecast
Leifheit Aktiengesellschaft: Distortions of the global supply chain affects EBIT in the third quarter, earnings (EBIT) forecast adjusted to EUR 15 to 20 million

13-Oct-2021 / 13:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Leifheit Aktiengesellschaft: Distortions of the global supply chain affects EBIT in the third quarter, earnings (EBIT) forecast adjusted to EUR 15 to 20 million

Nassau, 13 October 2021 - According to today's preliminary calculations Leifheit AG (ISIN DE0006464506) expects Group earnings before interest and taxes (EBIT) in the third quarter of the financial year 2021 of EUR 3.0 million (Q3 2020: EUR 6.6 million). After the first nine months of business year 2021 EBIT reached EUR 16.6 million, an increase of about 8 % compared to the previous year's figure of EUR 15.4 million.

Based on preliminary figures, the Leifheit Group reached a turnover of EUR 69.7 million in the third quarter 2021 (Q3 2020: EUR 71.6 million). In the first nine months of business year 2021 the Group achieved a turnover growth of 11.9 % to EUR 226 million (Q1-Q3 2020: EUR 201,9 million).

Further increases in raw material prices in the last few weeks as well as the low availability of cargo space and the associated cost increases and delivery bottlenecks affected the business development in the third quarter. The distortions in global supply chains will remain a challenge for the coming months. At the same time, necessary sales price increases can only be passed on to the market with a time lag and thus only have a partial effect in the current financial year.

Based on the preliminary figures for the third quarter the Management Board has reassessed the expectations for the Business year 2021. The Board of Management now assumes Group earnings before interest and taxes (EBIT) of between EUR 15 million and EUR 20 million. So far, an EBIT of EUR 20 million to EUR 24 million was expected. The turnover forecast remains unchanged, an increase of Group turnover of at least 5 % year-on-year is expected.

Information on the development in the third quarter is based on preliminary calculations. The final financial figures will be published in the quarterly statement on 11 November 2021.


Contact:
Leifheit AG
Petra Dombrowsky
Executive Assistant/CIRO
D-56377 Nassau
ir@leifheit.com
+49 2604 977218

13-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021